Yuki Kurahashi

Koka, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Orally available decitabine prodrug OR-2100 induces mitotic perturbation for the treatment of double-hit lymphoma.

Orally available decitabine prodrug OR-2100 induces mitotic perturbation for the treatment of double-hit lymphoma.

Journal: Blood neoplasia
Published: April 18, 2025

DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis.

DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis.

Journal: Leukemia
Published: February 14, 2024

Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.

Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.

Journal: Blood advances
Published: July 05, 2023

A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.

A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.

Journal: Cancers
Published: May 01, 2023

Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.

Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.

Journal: Cancer research communications
Published: July 01, 2022

Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.

Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.

Journal: Blood advances
Published: June 17, 2022

Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.

Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.

Journal: International journal of cancer
Published: August 12, 2021

Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.

Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.

Journal: Cancer letters
Published: June 29, 2021

Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.

Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.

Journal: Molecular cancer therapeutics
Published: December 28, 2020

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.

Journal: Blood
Published: August 27, 2019
Showing 1-10 of 10

Last Updated: 09/26/2026